Maryland Capital Management buys $20.8 Million stake in United Therapeutics Corporation (UTHR)

United Therapeutics Corporation (UTHR) : Maryland Capital Management scooped up 14,973 additional shares in United Therapeutics Corporation during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 12, 2016. The investment management firm now holds a total of 186,457 shares of United Therapeutics Corporation which is valued at $20.8 Million.United Therapeutics Corporation makes up approximately 3.10% of Maryland Capital Management’s portfolio.

Other Hedge Funds, Including , Sg Americas Securities boosted its stake in UTHR in the latest quarter, The investment management firm added 6,693 additional shares and now holds a total of 19,344 shares of United Therapeutics Corporation which is valued at $2.2 Million. United Therapeutics Corporation makes up approx 0.02% of Sg Americas Securities’s portfolio.Teachers Advisors Inc reduced its stake in UTHR by selling 12,699 shares or 23.35% in the most recent quarter. The Hedge Fund company now holds 41,693 shares of UTHR which is valued at $4.5 Million. United Therapeutics Corporation makes up approx 0.01% of Teachers Advisors Inc’s portfolio.Winton Capital Group Ltd boosted its stake in UTHR in the latest quarter, The investment management firm added 59,532 additional shares and now holds a total of 216,737 shares of United Therapeutics Corporation which is valued at $23.4 Million. United Therapeutics Corporation makes up approx 0.26% of Winton Capital Group Ltd’s portfolio.Ifp Advisors Inc boosted its stake in UTHR in the latest quarter, The investment management firm added 39 additional shares and now holds a total of 432 shares of United Therapeutics Corporation which is valued at $46,725.Great West Life Assurance Co Can reduced its stake in UTHR by selling 4,414 shares or 25.94% in the most recent quarter. The Hedge Fund company now holds 12,599 shares of UTHR which is valued at $1.3 Million.

United Therapeutics Corporation opened for trading at $111.02 and hit $114.12 on the upside on Friday, eventually ending the session at $113.62, with a gain of 2.55% or 2.82 points. The heightened volatility saw the trading volume jump to 4,41,961 shares. Company has a market cap of $5,061,657 M.

On the company’s financial health, United Therapeutics Corporation reported $3.02 EPS for the quarter, missing the analyst consensus estimate by $ -0.32 based on the information available during the earnings call on Apr 28, 2016. Analyst had a consensus of $3.34. The company had revenue of $369.00 million for the quarter, compared to analysts expectations of $397.24 million. The company’s revenue was up 12.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.55 EPS.

Many Wall Street Analysts have commented on United Therapeutics Corporation. United Therapeutics Corporation was Downgraded by Ladenburg Thalmann to ” Neutral” on Apr 29, 2016. Shares were Reiterated by RBC Capital Mkts on Apr 11, 2016 to “Sector Perform” and Lowered the Price Target to $ 122 from a previous price target of $150 .Shares were Reiterated by Wedbush on Mar 28, 2016 to “Outperform” and Lowered the Price Target to $ 229 from a previous price target of $238 .

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company’s key therapeutic products and product candidates include Remodulin Tyvaso (treprostinil) Adcirca (tadalafil) Remodulin Implantable System Orenitram Combination Therapy Esuberaprost and PLX Cells for the treatment of Pulmonary Arterial Hypertension; Ch14.18 MAb for the treatment of High-risk neuroblastoma; Ex-Vivo Lung Perfusion and Lung Transplantation for the treatment of End-stage lung disease; UV-4B for the treatment of Dengue and influenza and Glycobiology Antiviral Agents for the treatment of a spectrum of agents against viral infectious diseases among others. The Company’s lead product for treating Pulmonary Arterial Hypertension (PAH) is Remodulin.

Leave a Reply

United Therapeutics Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on United Therapeutics Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.